SARS-CoV-2 neutralizing antibody responses towards full-length spike protein and the receptor-binding domain

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

SARS-CoV-2 neutralizing antibody responses towards full-length spike protein and the receptor-binding domain. / Bayarri-Olmos, Rafael; Idorn, Manja; Rosbjerg, Anne; Pérez-Alós, Laura; Hansen, Cecilie Bo; Johnsen, Laust Bruun; Helgstrand, Charlotte; Zosel, Franziska; Bjelke, Jais Rose; Öberg, Fredrik Kryh; Søgaard, Max; Paludan, Søren R.; Bak-Thomsen, Theresa; Jardine, Joseph G.; Skjoedt, Mikkel Ole; Garred, Peter.

In: Journal of Immunology, Vol. 207, No. 3, 2021, p. 878-887.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Bayarri-Olmos, R, Idorn, M, Rosbjerg, A, Pérez-Alós, L, Hansen, CB, Johnsen, LB, Helgstrand, C, Zosel, F, Bjelke, JR, Öberg, FK, Søgaard, M, Paludan, SR, Bak-Thomsen, T, Jardine, JG, Skjoedt, MO & Garred, P 2021, 'SARS-CoV-2 neutralizing antibody responses towards full-length spike protein and the receptor-binding domain', Journal of Immunology, vol. 207, no. 3, pp. 878-887. https://doi.org/10.4049/jimmunol.2100272

APA

Bayarri-Olmos, R., Idorn, M., Rosbjerg, A., Pérez-Alós, L., Hansen, C. B., Johnsen, L. B., Helgstrand, C., Zosel, F., Bjelke, J. R., Öberg, F. K., Søgaard, M., Paludan, S. R., Bak-Thomsen, T., Jardine, J. G., Skjoedt, M. O., & Garred, P. (2021). SARS-CoV-2 neutralizing antibody responses towards full-length spike protein and the receptor-binding domain. Journal of Immunology, 207(3), 878-887. https://doi.org/10.4049/jimmunol.2100272

Vancouver

Bayarri-Olmos R, Idorn M, Rosbjerg A, Pérez-Alós L, Hansen CB, Johnsen LB et al. SARS-CoV-2 neutralizing antibody responses towards full-length spike protein and the receptor-binding domain. Journal of Immunology. 2021;207(3):878-887. https://doi.org/10.4049/jimmunol.2100272

Author

Bayarri-Olmos, Rafael ; Idorn, Manja ; Rosbjerg, Anne ; Pérez-Alós, Laura ; Hansen, Cecilie Bo ; Johnsen, Laust Bruun ; Helgstrand, Charlotte ; Zosel, Franziska ; Bjelke, Jais Rose ; Öberg, Fredrik Kryh ; Søgaard, Max ; Paludan, Søren R. ; Bak-Thomsen, Theresa ; Jardine, Joseph G. ; Skjoedt, Mikkel Ole ; Garred, Peter. / SARS-CoV-2 neutralizing antibody responses towards full-length spike protein and the receptor-binding domain. In: Journal of Immunology. 2021 ; Vol. 207, No. 3. pp. 878-887.

Bibtex

@article{cc0af31dd32247c1ae3b0e311993f329,

title = "SARS-CoV-2 neutralizing antibody responses towards full-length spike protein and the receptor-binding domain",

abstract = "Tools to monitor SARS-CoV-2 transmission and immune responses are needed. We present a neutralization ELISA to determine the levels of Ab-mediated virus neutralization and a preclinical model of focused immunization strategy. The ELISA is strongly correlated with the elaborate plaque reduction neutralization test (ρ = 0.9231, p < 0.0001). The neutralization potency of convalescent sera strongly correlates to IgG titers against SARS-CoV-2 receptor-binding domain (RBD) and spike (ρ = 0.8291 and 0.8297, respectively; p < 0.0001) and to a lesser extent with the IgG titers against protein N (ρ = 0.6471, p < 0.0001). The preclinical vaccine NMRI mice models using RBD and full-length spike Ag as immunogens show a profound Ab neutralization capacity (IC50 5 1.9 3 104 to 2.6 3 104 and 3.9 3 103 to 5.2 3 103, respectively). Using a panel of novel high-affinity murine mAbs, we also show that a majority of the RBD-raised mAbs have inhibitory properties, whereas only a few of the spike-raised mAbs do. The ELISA-based viral neutralization test offers a time- and cost-effective alternative to the plaque reduction neutralization test. The immunization results indicate that vaccine strategies focused only on the RBD region may have advantages compared with the full spike.",

author = "Rafael Bayarri-Olmos and Manja Idorn and Anne Rosbjerg and Laura P{\'e}rez-Al{\'o}s and Hansen, {Cecilie Bo} and Johnsen, {Laust Bruun} and Charlotte Helgstrand and Franziska Zosel and Bjelke, {Jais Rose} and {\"O}berg, {Fredrik Kryh} and Max S{\o}gaard and Paludan, {S{\o}ren R.} and Theresa Bak-Thomsen and Jardine, {Joseph G.} and Skjoedt, {Mikkel Ole} and Peter Garred",

year = "2021",

doi = "10.4049/jimmunol.2100272",

language = "English",

volume = "207",

pages = "878--887",

journal = "Journal of Immunology",

issn = "0022-1767",

publisher = "American Association of Immunologists",

number = "3",

}

RIS

TY - JOUR

T1 - SARS-CoV-2 neutralizing antibody responses towards full-length spike protein and the receptor-binding domain

AU - Bayarri-Olmos, Rafael

AU - Idorn, Manja

AU - Rosbjerg, Anne

AU - Pérez-Alós, Laura

AU - Hansen, Cecilie Bo

AU - Johnsen, Laust Bruun

AU - Helgstrand, Charlotte

AU - Zosel, Franziska

AU - Bjelke, Jais Rose

AU - Öberg, Fredrik Kryh

AU - Søgaard, Max

AU - Paludan, Søren R.

AU - Bak-Thomsen, Theresa

AU - Jardine, Joseph G.

AU - Skjoedt, Mikkel Ole

AU - Garred, Peter

PY - 2021

Y1 - 2021

N2 - Tools to monitor SARS-CoV-2 transmission and immune responses are needed. We present a neutralization ELISA to determine the levels of Ab-mediated virus neutralization and a preclinical model of focused immunization strategy. The ELISA is strongly correlated with the elaborate plaque reduction neutralization test (ρ = 0.9231, p < 0.0001). The neutralization potency of convalescent sera strongly correlates to IgG titers against SARS-CoV-2 receptor-binding domain (RBD) and spike (ρ = 0.8291 and 0.8297, respectively; p < 0.0001) and to a lesser extent with the IgG titers against protein N (ρ = 0.6471, p < 0.0001). The preclinical vaccine NMRI mice models using RBD and full-length spike Ag as immunogens show a profound Ab neutralization capacity (IC50 5 1.9 3 104 to 2.6 3 104 and 3.9 3 103 to 5.2 3 103, respectively). Using a panel of novel high-affinity murine mAbs, we also show that a majority of the RBD-raised mAbs have inhibitory properties, whereas only a few of the spike-raised mAbs do. The ELISA-based viral neutralization test offers a time- and cost-effective alternative to the plaque reduction neutralization test. The immunization results indicate that vaccine strategies focused only on the RBD region may have advantages compared with the full spike.

AB - Tools to monitor SARS-CoV-2 transmission and immune responses are needed. We present a neutralization ELISA to determine the levels of Ab-mediated virus neutralization and a preclinical model of focused immunization strategy. The ELISA is strongly correlated with the elaborate plaque reduction neutralization test (ρ = 0.9231, p < 0.0001). The neutralization potency of convalescent sera strongly correlates to IgG titers against SARS-CoV-2 receptor-binding domain (RBD) and spike (ρ = 0.8291 and 0.8297, respectively; p < 0.0001) and to a lesser extent with the IgG titers against protein N (ρ = 0.6471, p < 0.0001). The preclinical vaccine NMRI mice models using RBD and full-length spike Ag as immunogens show a profound Ab neutralization capacity (IC50 5 1.9 3 104 to 2.6 3 104 and 3.9 3 103 to 5.2 3 103, respectively). Using a panel of novel high-affinity murine mAbs, we also show that a majority of the RBD-raised mAbs have inhibitory properties, whereas only a few of the spike-raised mAbs do. The ELISA-based viral neutralization test offers a time- and cost-effective alternative to the plaque reduction neutralization test. The immunization results indicate that vaccine strategies focused only on the RBD region may have advantages compared with the full spike.

U2 - 10.4049/jimmunol.2100272

DO - 10.4049/jimmunol.2100272

M3 - Journal article

C2 - 34301847

AN - SCOPUS:85111666489

VL - 207

SP - 878

EP - 887

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 3

ER -

ID: 301343081

Department of Clinical Medicine